This year the conference brings its content, focused on the intersection of clinical research and patient care, from the real world to the virtual one.
The two companies are working together to develop AT-527, an orally administered, direct-acting antiviral therapy for patients diagnosed with COVID-19.
A leader from the drug research and development company discusses unique problems faced by COVID-19 patients with prior cancer and autoimmune diagnoses.
The agency has approved the antiviral drug Veklury (remdesivir), produced by Gilead, for hospitalized patients 12 years and over diagnosed with the virus.
The pharmaceutical firm’s More to uS is a UK-centered campaign that shares stories of people living (and thriving) after a multiple sclerosis diagnosis.
eClinical Solutions, a provider of clinical data service solutions, has seen an increase in interest in clinical data platform and other digital products.
A veteran with more than 20 years of experience talks about the vitality of recruiting an inclusive patient population, and the perils of falling short.
As the pandemic maintains its hold, the US agency continues to issue advice and take action related to testing, treatment and information on the virus.
Companies like Biofourmis, THREAD and other virtual tech specialists have seen infusions of funds from investors bullish on decentralized clinical trials.
TeleConsent empowers trial teams to obtain informed consent and re-consent from patients participating in clinical studies, within a fully remote system.
Ena Respiratory’s preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.
The technology combines predictive analytics and commercial services to help pharma firms and partners maximize drug discovery and development efforts.
The drug discovery and pharma companies have extended their agreement to collaborate on development of new treatments for a range of therapeutic areas.
A recent study from the clinical research services firm indicates the pandemic continues to significantly impact clinical trial sites around the globe.
A leader from Iqvia will present an overview of artificial intelligence, machine learning and other \technology during this year’s CPhI Festival of Pharma.
The technology from Opyl uses artificial intelligence to anticipate a COVID-19 treatment, vaccine, diagnostic or device’s chances of success in a study.